Preclinical research observed EGFR‐mutant cell lines exhibited olaparib (PARP inhibitor) sensitivity to a varying degree,22, 27 thus identification of NSCLC patients who could benefit from PARP inhibitor treatment is an important issue. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.